About DiaCarta

DiaCarta provides precise cancer molecular tests including NRAS, EGFR and KRAS mutation test kits, PCR ready lysis kit, HPV E6/E7 mRNA test kits for cervical and head-neck cancer, cancer biomarker gene expression detection kits and superfast master mix. DiaCarta supplies precise molecular diagnostic cancer assays that enable the most sensitive, reliable, and accurate detection of cancer biomarkers directly from a patient sample, including QClamp gene mutation tests, SuperbDNA gene expression

Company Highlights
Year Founded

2012

icon-altEmployees

46

Location (HQ)

USA

Since Last Funding

6 years 7 months

Monthly Website Visitors

8.2K

icon-altTotal Investment Amt

$53M

Last Funding Round

Series B

icon-altMoM Headcount Growth

-2.12%

icon-altYoY Headcount Growth

-6.11%

Key Metrics

Senior Hires

NameLinkedin ProfilePositionDate Joined
John Doehttps://www.linkedin.com/in/johndoeCEOCEO
Jane Doehttps://www.linkedin.com/in/janedoeCTOCTO
John Smithhttps://www.linkedin.com/in/johnsmithCFOCFO
Jane Smithhttps://www.linkedin.com/in/janesmithCOOCOO
Get API access to complete private company database with growth metrics from 15 sources

Biotechnology

Biotechnology Research

Medical

Genetics